Clinical Trials

140 enrolled

Breast Neoplasms, Carcinoma, Ductal

NCT06428396 2026-03-24

LITESPARK-029

120 enrolled

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT07395336 2026-02-09

COMBINE-01

26 enrolled

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Breast Neoplasms

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT06364267 2025-11-18

BabyTears

140 enrolled

Breast Neoplasms

NCT04272801 2025-10-22

POWER

84 enrolled 9 charts

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

247 enrolled 27 charts

Breast Neoplasms

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

200 enrolled

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT05463601 2025-05-14

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

132 enrolled

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

78 enrolled

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

37 enrolled 10 charts

Breast Neoplasms

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

103 enrolled 16 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

30 enrolled 10 charts

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT04465097 2023-10-17

NeoTEE

30 enrolled

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

55 enrolled

Breast Neoplasms

NCT02598557 2023-08-22

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

180 enrolled 46 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

202 enrolled 19 charts

Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

189 enrolled 17 charts

Breast Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

388 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00128843 2023-03-06

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

103 enrolled

Breast Neoplasms

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

118 enrolled 30 charts

Breast Neoplasms

NCT02440230 2022-12-30

SEAT

110 enrolled

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

73 enrolled

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

133 enrolled

Breast Neoplasms

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast Neoplasms

NCT00676663 2022-05-11

ENCORE301

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

NCT01831076 2022-03-03

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

36 enrolled 6 charts

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT02917005 2021-07-28

FATIMA

Phase 2 Unknown

160 enrolled

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04659551 2020-12-09

GIADA

43 enrolled

Breast Neoplasms

NCT00810797 2020-10-19

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

36 enrolled 8 charts

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled